Program
artenimol
Also written as “Eurartesim™”, “Dihydroartemisinin tablets” and “Eurartesim”.
Its studies are mostly in Malaria, Falciparum · Malaria, Vivax · Lupus Erythematosus, Discoid · Lupus Erythematosus, Systemic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| sigma-tau i.f.r. | 30 open or running | phase 1since Apr 12, 2010 | Apr 12, 2010 | none ahead |
| Kunming Pharmaceuticals | 21 open or running | phase 2since Jan 4, 2018 | Jan 4, 2018 | Sep 30, 2028phase 2 · NCT07557927 |
| Alfasigma | 10 open or running | phase 2since Apr 8, 2014 | Apr 8, 2014 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Jul 3, 2014 | Jul 3, 2014 | none ahead |
Also a collaborator on its studies: cpr-pharma-services-pty-ltd-australia.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 12, 2010First study: phase 1 study in Malaria, FalciparumNew to sigma-tau i.f.r.sigma-tau i.f.r. · NCT01103830 · 287 enrolled · France
- Oct 11, 20102 phase 1 studies in Malaria, Falciparumsigma-tau i.f.r. · NCT01222962, NCT01222949
- Apr 8, 2014Alfasigma's first study: phase 2 study in Malaria, VivaxNew to AlfasigmaAlfasigma · NCT02110784 · 27 enrolled · France, Germany, Israel and more
- Jul 3, 2014GlaxoSmithKline's first study: phase 1 study in Malaria, VivaxNew to GlaxoSmithKlineGlaxoSmithKline · NCT02184637 · 120 enrolled · United States
- Jan 4, 2018Kunming Pharmaceuticals's first study: phase 2 study in Lupus Erythematosus, SystemicNew to Kunming PharmaceuticalsKunming Pharmaceuticals · NCT03396393 · 120 enrolled
- Apr 22, 2026Phase 2 study in Lupus Erythematosus, DiscoidKunming Pharmaceuticals · NCT07557927 · 100 planned · China
Ahead
- Sep 30, 2028Primary completion: phase 2 study in Lupus Erythematosus, DiscoidKunming Pharmaceuticals · NCT07557927
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Ferriprotoporphyrin IX binding agent”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07557927Lupus Erythematosus, Discoid · China | 2 | Not yet recruiting | Kunming Pharmaceuticals | Sep 30, 2028 | 100 |
| NCT03396393Lupus Erythematosus, Systemic | 2 | UNKNOWN | Kunming Pharmaceuticals | Dec 2021 | 120 |
| NCT02184637Malaria, Vivax · United States | 1 | Completed | GlaxoSmithKline | Apr 8, 2015 | 120 |
| NCT02110784Malaria, Vivax · France, Germany, Israel and more | 2 | Terminated | Alfasigma | Nov 23, 2016 | 27 |
| NCT01222962Malaria, Falciparum · Australia | 1 | Completed | sigma-tau i.f.r. | May 2010 | 37 |
| NCT01222949Malaria, Falciparum · Australia | 1 | Completed | sigma-tau i.f.r. | Jul 2010 | 80 |
| NCT01103830Malaria, Falciparum · France | 1 | Completed | sigma-tau i.f.r. | Aug 2010 | 287 |
How it is read
Names in the registry
- “Eurartesim™”, 3 entries
- “Dihydroartemisinin tablets”, 2 entries
- “Eurartesim”, 2 entries
- “Eurartesim tablets”, 1 entry
- “Dihydroartemisinin tablet”, 1 entry
Conditions, from the studies’ own filings
- Malaria, Falciparum, 3 studies
- Malaria, Vivax, 2 studies
- Lupus Erythematosus, Discoid, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.